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ObesityAdiponectin (APN), an adipose-derived adipokine, offers cardioprotective effects although the precise mecha-
nism of action remains unclear. This studywas designed to examine the role of APN in high fat diet-induced obe-
sity and cardiac pathology. Adult C57BL/6 wild-type and APN knockout mice were fed a low or high fat diet for
22 weeks. After 40 day feeding, mice were treated with 2 mg/kg rapamycin or vehicle every other day for
42 days on respective fat diet. Cardiomyocyte contractile and Ca2+ transient properties were evaluated. Myocar-
dial function was evaluated using echocardiography. Dual energy X-ray absorptiometry was used to evaluate
adiposity. Energy expenditure, metabolic rate and physical activity were monitored using a metabolic cage.
Lipid deposition, serum triglyceride, glucose tolerance, markers of autophagy and fatty acid metabolism includ-
ing LC3, p62, Beclin-1, AMPK, mTOR, fatty acid synthase (FAS) were evaluated. High fat diet intake induced obe-
sity, systemic glucose intolerance, cardiac hypertrophy, dampened metabolic ability, cardiac and intracellular
Ca2+ derangements, the effects of which were accentuated by APN knockout. Furthermore, APN deﬁciency aug-
mented high fat diet-induced upregulation in the autophagy adaptor p62 and the decline in AMPK without
affecting high fat diet-induced decrease in LC3II and LC3II-to-LC3I ratio. Neither high fat diet nor APN deﬁciency
altered Beclin-1. Interestingly, rapamycin negated high fat diet-induced/APN-deﬁciency-accentuated obesity,
cardiac hypertrophy and contractile dysfunction as well as AMPK dephosphorylation, mTOR phosphorylation
and p62 buildup. Our results collectively revealed that APN deﬁciency may aggravate high fat diet-induced
obesity, metabolic derangement, cardiac hypertrophy and contractile dysfunction possibly through decreased
myocardial autophagy.
© 2013 Elsevier B.V. All rights reserved.1. Introduction
Obesity is among the major risk factors for myocardial dysfunction
and remodeling, leading to high cardiovascularmorbidity andmortality
[1–4]. In addition to genetic predisposition, both clinical and experi-
mental evidence has revealed a rather pivotal role of excessive fat and
caloric intake in the onset of obesity and accompanied inﬂammation,
cardiac hypertrophy, myocardial dysfunction, and mitochondrial injury
[5–7]. Although a number of scenarios including oxidative stress, in-
ﬂammation, apoptosis, endoplasmic reticulum stress and dyslipidemia
are speculated for obesity-induced cardiac anomalies [8–11], the ulti-
mate culprit factors remain elusive.
To date, several adipocyte-secreted factors are believed to play an
essential role in the onset and development of obesity and related
cardiovascular complications [12]. Among these, adiponectin (APN)
is an adipocyte-derived cytokine down-regulated in obesity. APN isearch and AlternativeMedicine,
e, WY 82071, USA. Tel.: +1 307
l rights reserved.capable of improving glucose and fat oxidation as well as retarding
progression of metabolic syndrome and cardiovascular diseases
such as cardiac hypertrophy, ischemic injury and atherosclerosis
[13–16]. APN is believed to offer its beneﬁcial myocardial effect
through modulation of pro-survival reactions, energy metabolism,
hypertrophic remodeling, and apoptotic, ﬁbrotic and inﬂammatory
response [17–20]. Deﬁciency in circulating APN may contribute to
cardiac hypertrophy, heart failure, insulin resistance and inﬂamma-
tion [14,21,22]. Recent evidence suggests that APN deﬁciency may
accelerate obesity, insulin resistance and hypertension following
high fat, high sucrose or high salt intake [23]. This is in line with
the reduced plasma APN levels in patients with obesity [24], type 2
diabetes [25], coronary artery disease [26] and hypertension [27].
It is reported that AMP-activated protein kinase (AMPK) and p38
mitogen-activated protein kinase (MAPK) serve as the major down-
stream mediators for APN [12,14,28]. APN deﬁciency exacerbates
heart failure due to impaired AMPK signaling and glucose metabolism
[19,21]. In addition, APN promotes glucose utilization and fatty acid
oxidation through AMPK activation [29]. However, the mechanisms
behind APN-induced cardiac response remain elusive. Recent evi-
dence has depicted a compelling role of autophagy, a highly conserved
Table 1
Biometric and echocardiographic parameters of mice fed low or high fat diet for 22 weeks.
Parameter WT-LF WT-HF APNKO-LF APNKO-HF
Body weight (BW, g) 25.4 ± 1.2 38.1 ± 1.7⁎ 26.9 ± 1.4 45.6 ± 2.9⁎,#
Heart weight (hw, mg) 131 ± 6 180 ± 5⁎ 137 ± 5 194 ± 11⁎,#
Tibial length (tl, mm) 19.9 ± 0.1 20.0 ± 0.1 19.8 ± 0.1 19.8 ± 0.1
HW/TL (mg/mm) 6.64 ± 0.28 8.99 ± 0.26⁎ 6.97 ± 0.28 9.79 ± 0.55⁎,#
Liver weight (LW, g) 1.22 ± 0.10 1.46 ± 0.10⁎ 1.27 ± 0.04 1.62 ± 0.10⁎,#
LW/TL (mg/mm) 61.4 ± 4.9 73.1 ± 5.2⁎ 64.1 ± 2.4 81.5 ± 4.6⁎,#
Kidney weight (KW, g) 0.34 ± 0.03 0. 40 ± 0.02 0.38 ± 0.03 0.50 ± 0.01⁎,#
KW/TL (mg/mm) 17.0 ± 1.2 20.2 ± 1.1 19.2 ± 1.6 25.4 ± 0.5⁎,#
White adipose tissue (g) 0.26 ± 0.02 2.13 ± 0.23⁎ 0.26 ± 0.01 2.59 ± 0.16⁎,#
Fat tissue (%) 15.8 ± 2.0 44.8 ± 4.4⁎ 16.0 ± 2.4 45.5 ± 3.5⁎
Tissue mass (g) 27.1 ± 0.6 34.5 ± 3.6 27.2 ± 0.3 42.2 ± 2.3⁎
Fat mass (g) 4.37 ± 0.53 15.87 ± 2.86⁎ 4.50 ± 0.67 19.17 ± 2.33⁎
Lean mass (g) 22.4 ± 0.6 19.7 ± 1.2 22.3 ± 0.7 22.3 ± 0.6
Serum TG (mg/dl) 19.0 ± 0.9 28.8 ± 2.8⁎ 22.4 ± 4.9 47.1 ± 6.6⁎#
Heart rate (bmp) 539 ± 17 516 ± 23 517 ± 27 510 ± 24
Wall thickness (mm) 0.96 ± 0.03 0.99 ± 0.05 1.01 ± 0.07 1.19 ± 0.09
LVEDD (mm) 2.09 ± 0.12 2.49 ± 0.18⁎ 2.17 ± 0.16 2.64 ± 0.11⁎
LVESD (mm) 1.13 ± 0.03 1.56 ± 0.12⁎ 1.18 ± 0.08 1.71 ± 0.12⁎
LV mass (mg) 40.4 ± 4.2 53.4 ± 2.7⁎ 46.3 ± 6.2 74.5 ± 8.1⁎#
Fractional shortening (%) 48.0 ± 2.4 37.5 ± 1.8⁎ 48.8 ± 2.3 35.8 ± 2.5⁎
Mean ± SEM, n = 9 mice per group.
⁎ p b 0.05 vs. WT-LF group.
# p b 0.05 vs. WT-HF group.
1137R. Guo et al. / Biochimica et Biophysica Acta 1832 (2013) 1136–1148homeostatic process governing the turnover of long-lived proteins and
cytoplasmic components including damaged organelles and dysfunc-
tional proteins, in the regulation of adipogenesis, obesity, insulin sensi-
tization, cardiac structure and function [30–32]. Under physiological
conditions, autophagy plays an important role in the maintenance of
cardiac geometry and function [33,34]. Impaired autophagy is present
in a number of heart diseases such as ischemia perfusion injury and di-
abetes [34,35]. Reduced hepatic and cardiac autophagy was shown in
obesity [32,36–38]. To this end, a thorough understanding of the rela-
tionship between autophagy and APN may provide a better rationale
for the application of APN in obesity-associatedmyocardial dysfunction.WT-LF
APNKO-HFWT-HF
APNKO-LF
H&E Cross-Sectional AreaC)
APNKO-LFWT-LF WT-HF
A) B)
APNKO-HF 
Fig. 1. Effect of adiponectin knockout (APNKO) on high fat diet intake-induced obesity an
mice fed low (LF) or high fat (HF) diet; B: Representative photographs of white adipose tis
transverse sections of left ventricular myocardium (×400) fromWT and APNKOmice fed LF or
measurements of ~100 cardiomyocytes from5mice per group; E: Representative gross images
fed LF or HF diet; and G: Body weight changes of mice fed LF or HF diet. Mean ± SEM, n = 9Our present studywas designed to evaluate the impact of APN deﬁcien-
cy on high fat diet-induced metabolic disorder and cardiac anomalies.
We hypothesized that APN deﬁciency-elicited response under high fat
diet intakemay bemediated through autophagy regulation. To evaluate
a possible role of autophagy, mice were treated with rapamycin every
other day for 42 days while consuming low or high fat diet. Food and
calorie intake, adiposity, lipid deposition, energy expenditure, O2 con-
sumption, CO2 production, physical activity, intracellular Ca2+ handling,
cardiac geometry and function were examined. Serum triglyceride,
glucose tolerance test and protein markers for autophagy pathway in-
cluding LC3, p62, Beclin-1, AMPK and mTOR were also monitored.WT
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d cardiac hypertrophy. A: Representative photographs of wild type (WT) and APNKO
sues (WAT) in WT and APNKO mice fed LF or HF diet; C: H&E staining micrographs of
HF diet; D: Quantitative analysis of cardiomyocyte cross-sectional (transverse) area using
of hearts inWT andAPNKOmice fed LF or HF diet; F: Averageweekly calorie intake inmice
mice per group, *p b 0.05 vs.WT-LF group, #p b 0.05 vs.WT-HF group.
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2.1. Experimental animals, high fat diet feeding, body fat composition
and intraperitoneal glucose tolerance test (IPGTT)
The experimental procedure was approved by our Institutional
Animal Use and Care Committee (Laramie, WY) and was in compliance
with the Guide for the Care and Use of Laboratory Animals published by
NIH (Publication No. 85-23, revised 1996). In brief, 4 month-old male
WT and APN knockout (APNKO) mice weighing ~28 g were randomly
assigned to a low fat (10% of calories from fat) or a high fat (45% of
total calories from fat) diet (Research Diets Inc., New Brunswick, NJ)
for 22 weeks. APNKOmice were genotyped by PCR using the following
primers: TGG ATG CTG CCA TGT TCC CAT (WT forward), CTT GTG TCT
GTG TCT AGG CCT T (WT reverse) and CTC CAG ACT GCC TTG GGA
(mutant reverse). To assess the effect of autophagy in fat diet-induced
cardiac mechanical response, mice fed low or high fat for 40 days
were treated with or without the autophagy inducer rapamycin
(2 mg/kg, i.p., dissolved in 4% ethanol, 5% PEG-300 and 5% Tween-80)
or vehicle every other day for 42 days while being maintained on re-
spective diet [39–41]. Mice were housed in a climate-controlled envi-
ronment (22.8 ± 2.0 °C, 45–50% humidity) with a 12/12-light/dark
cycle with free access to food and water. Body weight and food in-
take were measured weekly. Following 22-week feeding, body fatWT
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Fig. 2. Metabolic properties of WT and APNKO mice fed LF or HF diet. A: O2 consumption;
G: Energy expenditure. Mean ± SEM, n = 6 mice per group, *p b 0.05 vs. WT-LF group, #pcomposition (% fat mass) was measured using Dual Energy X-ray
Absorptiometry (GE Lunar Prodigy™ 8743; Madison, WI). Difference
in X-ray absorbance was detected based on tissue density. Body fat
composition was calculated using body fat and body mass. Mice fasted
for 12 h were then given an intraperitoneal (i.p.) injection of glucose
(2 g/kg b.w.). Blood samples were drawn from the tail vein immediate-
ly before glucose challenge, aswell as 15, 60, 90 and 120 min thereafter.
Serum glucose levels were determined using an Accu-Chek III glucose
analyzer. Area under the curve (AUC) was calculated using trapezoidal
analysis.
2.2. Metabolic measurement
The Comprehensive Laboratory AnimalMonitoring System (CLAMS™,
Columbus Instruments, Columbus, OH) is a set of live-in cages for auto-
mated, non-invasive and simultaneous monitoring of food and water
consumption, horizontal and vertical activity, and metabolic perfor-
mance [42]. Following 22 weeks of diet feeding, WT and APNKO mice
(with or without rapamycin injection) were individually placed in the
CLAMS metabolic cages with ad libitum access to food and water.
Following acclimation metabolic parameters including volume of
carbon dioxide produced (VCO2), the volume of oxygen consumed
(VO2), the respiratory exchange ratio (RER = VCO2/VO2), the caloric
(heat) value: [(3.815 + 1.232 × RER) × VO2] × 1000/body weightHF
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Fig. 3. Intraperitoneal glucose tolerance test (IPGTT, 2 g/kg, i.p.) in WT and APNKO
mice fed LF or HF diet. A: Serum glucose levels within 120 min following acute glucose
challenge; and B: Area underneath the curve (AUC). Mean ± SEM, n = 6–12 mice per
group, *p b 0.05 vs. WT-LF group, #p b 0.05 vs. WT-HF group.
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termined. Data were collected every 12 min over a 6-h period at night.
2.3. Echocardiographic assessment
Cardiac geometry and function were evaluated in anaesthetized
(ketamine 80 mg/kg and xylazine 12 mg/kg, ip) mice using a two-
dimensional (2D) guided M-mode echocardiography (Phillips Sonos
5500) equipped with a 15-6 MHz linear transducer (Phillips Medical
Systems, Andover, MD, USA). Adequate depth of anesthesia was
monitored using toe reﬂex. The heart was imaged in the 2-D mode
in the parasternal long-axis view with a depth of 2 cm. The M-mode
cursor was positioned perpendicular to interventricular septum
and posterior wall of left ventricle (LV) at the level of papillary
muscles from the 2-D mode. Heart rate, diastolic wall thickness,
end diastolic dimension (EDD) and end systolic dimension (ESD)
were measured. All measurements were done from leading edge to
leading edge in accordance with the Guidelines of the American
Society of Echocardiography [43]. LV mass was calculated as 1.05
[(LVIDD + PWTD + IVSTD)3 − (LVIDD)3] g. LV fractional shortening
was calculated as [(EDD-ESD) / EDD] × 100. Heart rate was averaged
over 10 cardiac cycles [44].
2.4. Serum triglyceride level
Serum triglyceride level was measured using an assay kit from
Biovision (Mountain View, CA). In brief, serum samples were prepared
(50 μl/well) with the triglyceride assay buffer in a 96-well plate prior to
addition of lipase and the reactionmix. Triglyceride levels weremea-
sured using the Spectra Max 190 Microplate Spectrophotometer
(Molecular Devices, Sunnyvale, CA) [45].
2.5. Cardiac histological analysis
To evaluate the cross-sectional area and accumulation of lipid
droplets (LD), H&E and Oil-Red-O staining were examined. Following
anesthesia (ketamine 80 mg/kg and xylazine 12 mg/kg, i.p), hearts
were excised and immediately placed in 10% neutral-buffered formalin
at room temperature for 24 h after a brief rinsewith PBS. Thereafter, tis-
sues were dehydrated through serial alcohol and cleared in xylene. The
specimens were embedded in parafﬁn, cut into 5 μm sections and
stained with hematoxylin and eosin (H&E) [46]. For Oil-Red-O staining,
heartswere sliced and snap-frozen in isopentane-cooled liquid nitrogen
before cutting into 10-μm sections with a cryostat. The sections were
ﬁxed with 10% neutral-buffered formalin, rinsed with 60% isopropanol
and stained with Oil-Red-O for 15 min. After rinsing with isopropanol,
sections were counterstained and mounted with aqueous mountant
(Vector Laboratories Ltd., Burlingame, CA) [47]. A digital Olympus
BX-51 microscope (×400) (Olympus America Inc., Melville, NY) was
used to digitalize the sections. Quantiﬁcation of cross-sectional area
from H&E staining was calculated using the Image J (version1.43, NIH)
software [48].
2.6. Isolation of murine cardiomyocytes and rapamycin treatment
WT and APNKO mice fed low fat or high fat diet were challenged
with rapamycin or vehicle in vivo (2 mg/kg, i.p.) every other day for
42 days. After ketamine/xylazine sedation (ketamine 80 mg/kg and
xylazine 12 mg/kg, i.p), hearts were removed and perfused with
Ca2+-free Tyrode's solution containing (in mM): NaCl 135, KCl 4.0,
MgCl2 1.0, HEPES 10, NaH2PO4 0.33, glucose 10, butanedione monoxime
10, and the solutionwas gassedwith 5%CO2/95%O2.Heartsweredigested
with Liberase Blendzyme 4 (Hoffmann-La Roche Inc., Indianapolis, IN) for
15 min. Left ventricles were removed and minced before being ﬁltered.
Tissue pieces were gently agitated and pellet of cells was resuspended.
Extracellular Ca2+ was added incrementally back to 1.20 mM. To assessthe acute effect of rapamycin on cardiomyocyte contractile function
following high fat diet feeding, ex vivo experiment was performed. In
brief, cardiomyocytes from WT and APNKO mice on low fat or high
fat diet were treated with or without rapamycin (5 μM, 4 h) [49]
prior to evaluation of mechanical properties. Cardiomyocytes were
used within 8 h of isolation. A yield of 50–60% viable rod-shaped
cardiomyocytes with clear sarcomere striations was achieved. Only
rod-shaped cardiomyocytes with clear edges were selected for me-
chanical study.
2.7. Cell shortening/relengthening
Mechanical properties of cardiomyocytes were assessed using
a SoftEdge MyoCam system (IonOptix Corporation, Milton, MA).
Cardiomyocytes were placed in a Warner chamber mounted on the
stage of an inverted microscope (Olympus IX-70) and superfused
(~1 ml/min at 25 °C) with a buffer containing (in mM) 131 NaCl, 4
KCl, 1 CaCl2, 1 MgCl2, 10 glucose, and 10 HEPES at pH 7.4. The cells
were ﬁeld stimulated with suprathreshold voltage at a frequency of
0.5 Hz, 3 ms duration, using a pair of platinumwires placed on opposite
sides of the chamber connected to a FHC stimulator (Brunswick, NE). The
myocyte being studiedwas displayed on the computermonitor using an
IonOptix MyoCam camera. IonOptix SoftEdge software was used to cap-
ture changes in cell length during shortening and relengthening. Cell
shortening and relengtheningwere assessed using the following indices:
peak shortening (PS), time-to-PS (TPS), time-to-90% relengthening
(TR90), andmaximal velocity of cell shortening/relengthening (±dL/dt).
2.8. Intracellular Ca2+ ﬂuorescence
Cardiomyocytes were loaded with fura-2/AM (0.5 μM) for 10 min
and ﬂuorescence measurements were recorded using a dual-excitation
ﬂuorescence photo multiplier system (IonOptix). Cardiomyocytes were
1140 R. Guo et al. / Biochimica et Biophysica Acta 1832 (2013) 1136–1148placed on an Olympus IX-70 inverted microscope and imaged through a
Fluor 40× oil objective. Cells were exposed to light emitted by a 75 W
lamp and passed through either a 360 or a 380 nm ﬁlter, while being
stimulated to contract at 0.5 Hz. Fluorescence emissions were detected
between 480 and 520 nm by a photomultiplier tube after ﬁrst illuminat-
ing the cells at 360 nm for 0.5 s then at 380 nm for the duration of the
recording protocol (333 Hz sampling rate). The 360 nm excitation scan
was repeated at the end of the protocol and qualitative changes in
intracellular Ca2+ concentration were inferred from the ratio of
fura-2 ﬂuorescence intensity at two wavelengths (360/380). Fluo-
rescence decay time was assessed as an indication of intracellular
Ca2+ clearing.
2.9. Western blot analysis
Total protein was prepared as described [50]. In brief, tissue sam-
ples from fed mouse ventricles were removed and homogenized in a
lysis buffer containing 10% 10× RIPA, 1% NaF, 1% Na3VO4 and 1% pro-
tease inhibitor cocktail. Samples were sonicated on ice for 15 s and
centrifuged at 13,000 rpm for 20 min at 4 °C. Murine cardiomyocytes
were collected and sonicated in a lysis buffer. The protein concentration ofWT
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with Laemmli sample buffer with 5% 2-mercaptoethanol and heated at
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separated on 7%, 10% or 15% SDS-polyacrylamide gels in a minigel appa-
ratus (Mini-PROTEAN II, Bio-Rad) and transferred electrophoretically to
nitrocellulose membranes (0.2 μm pore size, Bio-Rad Laboratories, Inc.).
Membranes were incubated for 1 h in a blocking solution containing 5%
milk in Tris-buffered saline (TBS). Membranes were washed brieﬂy in
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(1:1000, Thr172), anti-AMPKα (1:1000), anti-phospho-mTOR
(1:1000, Ser2448), anti-mTOR (1:1000), anti-Beclin-1 (1:1000),
anti-LC3B (1:500), anti-p62 (1:1000), anti-fatty acid synthase
(1:500), anti-GAPDH (loading control, 1:1000) and anti-α-tubulin
(loading control, 1:1000) antibodies. After washing blots to remove
excessive primary antibody binding, blots were incubated for 1 h with
horseradish peroxidase (HRP)-conjugated secondary antibody (1:2500).
Antigens were detected by the luminescence method. Quantiﬁcation of
band density was determined using Quantity One software (Bio-Rad,
version 4.4.0, ChemiDoc XRS) and reported in optical density per square
millimeter.WT
-LF
WT
-H
F
AP
NK
O-
LF
AP
NK
O-
HF
0
50
100
150
200
250
*
*
In
tr
ac
el
lu
la
r C
a2
+  
D
ec
ay
 
R
at
e 
(m
se
c)
PN
KO
-LF
AP
NK
O-
HF
*
#
PN
KO
-LF
AP
NK
O-
HF
*
#
WT
-LF
WT
-H
F
AP
NK
O-
LF
AP
NK
O-
HF
0
100
200
300
* *
TR
90
 (m
se
c)
C
F
WT
-LF
WT
-H
F
AP
NK
O-
LF
AP
NK
O-
HF
0
50
100
150
*
*
#
+
 d
L/
dt
 (  
m/
se
c)
AP
NK
O-
LF
AP
NK
O-
HF
#*
I
m WT and APNKO mice fed LF or HF diet. A: Resting cell length; B: Peak shortening
ning (−dL / dt); E: Time-to-PS (TPS); F: Time-to-90% relengthening (TR90); G: Resting
and I: intracellular Ca2+ decay rate. Mean ± SEM, n = 110 cells from 3mice per group,
WT
-LF
WT
-H
F
AP
NK
O-
LF
AP
NK
O-
HF
0.0
0.5
1.0
1.5
2.0
2.5
*
#
*
WT
-LF
WT
-H
F
AP
NK
O-
LF
AP
NK
O-
HF
0.0
0.5
1.0
1.5
2.0
2.5
A
M
P
K
 
 
 
E
x
p
r
e
s
s
i
o
n
(
A
r
b
i
t
r
a
r
y
 
O
p
t
i
c
a
l
 
D
e
n
s
i
t
y
)
WT
-LF
WT
-H
F
AP
NK
O-
LF
AP
NK
O-
HF
0.0
0.2
0.4
0.6
m
T
O
R
 
E
x
p
r
e
s
s
i
o
n
(
A
r
b
i
t
r
a
r
y
 
O
p
t
i
c
a
l
 
D
e
n
s
i
t
y
)
WT
-LF
WT
-H
F
AP
NK
O-
LF
AP
NK
O-
HF
0.0
0.2
0.4
0.6
0.8
1.0
#
*
p
-
m
T
O
R
 
E
x
p
r
e
s
s
i
o
n
(
A
r
b
i
t
r
a
r
y
 
O
p
t
i
c
a
l
 
D
e
n
s
i
t
y
)
WT
-LF
WT
-H
F
AP
NK
O-
LF
AP
NK
O-
HF
0.0
0.2
0.4
0.6
B
e
c
l
i
n
-
1
 
E
x
p
r
e
s
s
i
o
n
(
A
r
b
i
t
r
a
r
y
 
D
e
n
s
i
t
y
)
WT
-LF
WT
-
HF
AP
NK
O-
LF
AP
NK
O-
HF
0
1
2
3
*
#
*
p
-
m
T
O
R
-
t
o
-
m
T
O
R
 
R
a
t
i
o
WT
-LF
WT
-H
F
AP
NK
O-
LF
AP
NK
O-
HF
0.0
0.2
0.4
0.6
0.8
1.0
*
#
*
p
6
2
 
E
x
p
r
e
s
s
i
o
n
(
A
r
b
i
t
r
a
r
y
 
D
e
n
s
i
t
y
)
WT
-LF
WT
-H
F
AP
NK
O-
LF
AP
NK
O-
HF
0.0
0.5
1.0
1.5
*
#*
p
-
A
M
P
K
-
t
o
-
A
M
P
K
 
R
a
t
i
o
WT
-
LF
WT
-H
F
AP
NK
O-
LF
AP
NK
O-
HF
0.0
0.5
1.0
1.5
2.0
2.5
L
C
3
I
 
E
x
p
r
e
s
s
i
o
n
(
A
r
b
i
t
r
a
r
y
 
D
e
n
s
i
t
y
)
WT
-LF
WT
-H
F
AP
NK
O-
LF
AP
NK
O-
HF
0.0
0.2
0.4
0.6
0.8
1.0
* *
L
C
3
I
I
 
E
x
p
r
e
s
s
i
o
n
(
A
r
b
i
t
r
a
r
y
 
D
e
n
s
i
t
y
)
WT
-LF
WT
-H
F
AP
NK
O-
LF
AP
NK
O-
HF
0.0
0.1
0.2
0.3
0.4
0.5
* *
L
C
3
I
I
-
t
o
-
L
C
3
I
 
R
a
t
i
o
 -Tubulin
p-AMPK
62 KD
62 KD
55 KD
AMPK
A C
E
B
Beclin-1
p62
LC3II/I
GAPDH
62 KD
14/16 KD
37 KD
60 KD
LKJI
F G
p-mTOR
289 KD
289 KD
mTOR
D
H
p
-
A
M
P
K
 
 
 
 
E
x
p
r
e
s
s
i
o
n
(
A
r
b
i
t
r
a
r
y
 
O
p
t
i
c
a
l
 
D
e
n
s
i
t
y
)
Fig. 5. Expression of AMPK, mTOR and autophagy markers in myocardium from WT and APNKO mice fed LF or HF diet. All mice were fed prior to collection of myocardial tissues. A: Representative gel blots depicting levels of pan and
phosphorylated AMPKα and mTOR, p62, LC3B, Beclin-1, α-tubulin and GAPDH (loading controls); B: AMPKα; C: p-AMPKα; D: p-AMPK-to-AMPK ratio; E: mTOR; F: p-mTOR; G: p-mTOR-to-mTOR ratio; H: Beclin-1; I: p62; J: LC3I; K: LC3II;
and L: LC3II-to-LC3I ratio. Mean ± SEM, n = 6–8 mice per group, *p b 0.05 vs.WT-LF group, #p b 0.05 vs.WT-HF group.
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Data were mean ± SEM. Statistical signiﬁcance (p b 0.05) for each
variable was estimated by analysis of one-way or two-way variance
(ANOVA) followed by Tukey's post hoc analysis.
3. Results
3.1. Biometric parameters and myocardial histology in mice with low or
high fat diet
High fat diet signiﬁcantly increased body and organ (heart and
liver) weights, heart size (normalized to tibial length), white adipose
tissueweight and serum triglycerides, the effects of whichwere exacer-
bated by APN deﬁciency (Table 1, Fig. 1A–B). Consistently, H&E staining
revealed that high fat diet intake overtly increased cardiomyocyte
cross-sectional area with a more pronounced effect in APNKO mice.There was little difference in the appearance of myocardial histology
between WT and APNKO mice consuming low fat diet (Fig. 1C–D).
Gross morphology displayed enlarged hearts in WT and APNKO mice
following high fat diet feeding (Fig. 1E). Similarly, fat mass and tissue
fat composition (% fat) were increased in a comparable manner in WT
and APNKO mice following high fat intake (Table 1). Furthermore,
high fat diet triggered dramatic increases in kidney weight and tissue
mass (fat mass + lean mass) in APNKO but not WT mice. Neither fat
diet nor APN deﬁciency affected lean mass. In addition, there were no
apparent differences in calorie intake and body weight gain between
WT and APNKO mice consuming low fat diet for 22 weeks. However,
calorie intake was signiﬁcantly lower in APNKO mice compared with
WTmice consuminghigh fat feeding (Fig. 1F). As expected, bodyweight
was dramatically increased in WT and APNKO mice following high fat
diet feeding, the effect of which was exaggerated by APN deﬁciency at
as early as twoweeks after high fat diet intake (Fig. 1G). APN deﬁciency
itself had little effect on these parameters tested.
1143R. Guo et al. / Biochimica et Biophysica Acta 1832 (2013) 1136–11483.2. Echocardiographic properties in WT and APNKO mice with low or
high fat diet
As shown in Table 1, high fat diet signiﬁcantly increased LVEDD,
LVESD and LV mass in WT and APNKO mice. Moreover, APN deﬁcien-
cy remarkably exacerbated the increase in LV mass following high fat
diet intake, indicating an aggravating effect of APN deﬁciency in car-
diac remodeling. However, heart rate and LV wall thickness were un-
affected by high fat diet feeding inWTmice, although there is a subtle
trend of increase of wall thickness in APNKO mice consuming high fat
diet. In addition, high fat feeding signiﬁcantly depressed fractional
shortening in a comparable manner in both WT and APNKO mice.
APN knockout itself did not affect any of the echocardiographic indices
tested.3.3. APN deﬁciency aggravated high fat diet-induced retardation of the
metabolic ability and decreased fat oxidation
As shown in Fig. 2, high fat diet feeding resulted in decrease of O2
consumption and CO2 production, the effect of which was augmented
by APN deﬁciency. RER was decreased from ~0.93 in low fat WT mice
to ~0.73 in high fat-fedWTmice. However, APN deﬁciency signiﬁcant-
ly increased RER compared with the fat diet-matched WT mice, indi-
cating a blunted fat oxidation following high fat feeding in APNKO
mice.Moreover, physical activity and energy expenditure (heat release)
were dramatically deceased in APNKO but not WT mice following high
fat feeding. APN knockout itself failed to alter any of the metabolic
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by high fat diet
Following intraperitoneal glucose challenge, serum glucose levels
started to decline after peaking at 15 min and nearly returned to
baseline values after 120 min in low fat diet-fed mice. However, the
post-challenge glucose levels remained at higher levels between 15 and
120 min in high fat-fed WT mice, the effect of which was exaggerated
by APN deﬁciency, indicating profound systematic glucose intolerance.
Area under the IPGTT curve further conﬁrmed the presence of glucose
intolerance following high fat diet feeding in WT and APNKO mice. APN
deﬁciency alone had little effect on glucose tolerance. It is noteworthy
that basal fasting glucose levels were comparable among all mouse
groups, thus excluding the possible contribution of full-blown diabetes
(Fig. 3A–B).3.5. Cardiomyocyte contractile and intracellular Ca2+ properties
Fig. 4A–F depicts that high fat diet intake increased resting cell length
in APN knockout but not in WT mice. High fat diet intake signiﬁcantly
reduced peak shortening (PS) and maximal velocity of shortening/
relengthening (±dL/dt) aswell as prolonged time-to-90% relengthening
(TR90) without affecting time-to-PS (TPS) in cardiomyocytes from WT
mice. Importantly, APN deﬁciency exacerbated high fat diet-induced
mechanical abnormalities (with the exception of prolonged TR90) with-
out eliciting any notable effect by itself. In addition, data presented in
Fig. 4G–H reveals signiﬁcantly depressed intracellular Ca2+ rise in
response to electrical stimulus [shown as the increase in Fura-2APNKO-HF
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rate associated with unchanged resting intracellular Ca2+ levels in cells
from high fat-fedWT mice. Although APN deﬁciency itself did not affect
intracellular Ca2+ handling, it further accentuated high fat diet-induced
depression in ΔFFI without affecting high fat diet-induced responses in
intracellular Ca2+ decay or resting intracellular Ca2+ levels.3.6. APN deﬁciency aggravated fat diet-induced decrease in autophagy
and AMPK activation
To examine the potential impact of APN deﬁciency on high fat diet
intake-induced metabolic disturbance and autophagic response, ex-
pression of the energy fuel signal AMPK, the autophagy markers
Beclin-1, LC3I/II and the autophagy cargo adaptor p62 were evaluated
in myocardium from WT and APNKO mice following high fat feeding.
Immunoblotting results shown in Fig. 5 revealed an overt decline in
LC3II level and LC3II-to-LC3I ratio, upregulated p62 expression without
changes in LC3I and Beclin-1 in myocardium from WT mice following
high fat diet feeding. Although APN deﬁciency did not affect levels of
these autophagymarkers, it accentuated high fat diet-induced inhibition
of autophagy as manifested by a further increase in p62 level along with
comparably reduced LC3II level and LC3II-to-LC3I ratio as well as a trend
of reduced Beclin-1. Along the same line, high fat diet intake overtly
suppressed AMPK phosphorylation (absolute value or normalized to
AMPKα), the effect of whichwas ampliﬁed by APN deﬁciency, indicatingWT-HF APN-HF
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3.7. Rapamycin reversed APN deﬁciency-induced drop of fat oxidation in
high fat diet feeding
Our data in Fig. 6 revealed that rapamycin treatment for 42 days
restored high fat diet intake-induced reduction in O2 consumption
and CO2 production. More importantly, RER signiﬁcantly rebounded
to ~0.9 following rapamycin administration in WT and APNKO mice
consuming high fat diet. This beneﬁcial effect may be attributed to
loss in body weight and adipose tissues in response to rapamycin
treatment under high fat diet intake as opposed to abnormal fat oxi-
dation. Furthermore, physical activity and energy expenditure were
completely or partially restored to normal levels in high fat fed mice
following rapamycin treatment.
3.8. Rapamycin reduced high fat diet-induced obesity and
cardiac hypertrophy
Rapamycin treatment for 42 days effectively reversed or signiﬁcantly
attenuated high fat diet-induced increases in body weight, heart weight
and heart size (normalized to tibial length), as well as weight of white
adipose tissue in both WT and APNKO mice (Fig. 7 and Table S1). InWT
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1145R. Guo et al. / Biochimica et Biophysica Acta 1832 (2013) 1136–1148addition, H&E staining reveals that rapamycin treatment reduced high
fat diet intake-induced enlargement in cardiomyocytes. Rapamycin itself
failed to signiﬁcantly alter body weight, organ weight, organ size and
cardiomyocyte cross-sectional area in low fat diet-fed mice (Fig. 7).
3.9. Effect of rapamycin treatment on APN deﬁciency-accentuated glucose
intolerance and cardiac lipid accumulation around blood vessels following
high fat diet intake
Our data revealed that high fat diet led to overt glucose intolerance
and lipid deposition around myocardial blood vessels along with the
upregulation of fatty acid synthase, the effects ofwhichwere exacerbated
by APN deﬁciency. Rapamycin treatment for 42 days failed to improve
high fat diet intake-induced glucose intolerance in both WT and APNKO
mice. After rapamycin injection, serum glucose levels remained high
between 15 and 120 min in WT and APNKO mice consuming high fat
diet, reminiscent of those without rapamycin treatment. The same
pattern was seen using area under the IPGTT curve (AUC). Notably,
rapamycin treatment nulliﬁed high fat diet-induced abnormal fat accu-
mulation and elevation in FAS level in both WT and APNKO mice
(Fig. 8). These results demonstrated that rapamycin treatment may
exert its beneﬁcial effect against high fat intake and/or APN deﬁciency
through corrected cardiac lipid accumulation rather than improved global
glucose metabolism.
3.10. Rapamycin attenuated high fat diet intake and/or APN deﬁciency-
induced cardiomyocyte contractile dysfunction
Our data shown in Fig. 9 revealed that rapamycin treatment both in
vivo (i.p.) and ex vivo (5 μM, 4 h) ablated or signiﬁcantly attenuatedWT
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Fig. 9. Effect of rapamycin (RAPA) in vivo (2 mg/kg, i.p. every other day for 42 days, i.p.) and
LF or HF diet. A: Resting cell length; B: Peak shortening (% of cell length); C: Maximal veloc
E: Time-to-PS (TPS); and F: Time-to-90% relengthening (TR90); Mean ± SEM, n =
WT-HF group, †p b 0.05 vs. APNKO-HF group.high fat diet-induced cardiomyocyte mechanical anomalies (manifested
as depressed PS, ±dL/dt, prolonged TPS and TR90) in WT and APNKO
mice. Interestingly, chronic in vivo but not short-term ex vivo rapamycin
treatment signiﬁcantly alleviated the increased resting cell length in
APNKO mice fed high fat diet. Rapamycin itself (in vivo or ex vivo) did
not elicit any signiﬁcant effect on cardiomyocyte contractile properties.
3.11. Rapamycin reversed APN deﬁciency-induced changes of mTOR,
AMPKα and autophagy following high fat diet feeding
Immunoblotting results shown in Fig. 10 revealed that APN deﬁ-
ciency accentuated high fat diet intake-induced loss of AMPKα phos-
phorylation (absolute vale or normalized to AMPKα) and LC3B, as
well as rises in mTOR phosphorylation (absolute value or normalized to
mTOR) and p62 levels, the effects of which were reversed by rapamycin
treatment. As expected, the autophagy inducer rapamycin promoted
AMPKα phosphorylation and LC3B as well as inhibited mTOR phosphor-
ylation (without eliciting any notable effect on p62) in low fat diet-fed
WT and APNKO mice. Total protein expression of AMPKα and mTOR
was unaffected by high fat diet intake or APN deﬁciency, in the presence
or absence of rapamycin treatment (Fig. S1).
4. Discussion
The salient ﬁndings of our present study indicated that APN deﬁ-
ciency aggravates high fat diet-induced obesity, glucose intolerance,
metabolic disturbance, cardiac hypertrophy and contractile dysfunction
as well as overt downregulation of autophagy. More importantly, results
from our present study also revealed that rapamycin, an autophagy
inducer, improved high fat diet-induced/APN deﬁciency-accentuatedHF
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Fig. 10. Effect of rapamycin treatment (RAPA, 2 mg/kg/2 days for 42 days, i.p.) on high fat (HF) diet-induced changes in the levels of phosphorylated AMPK and mTOR as well as the
autophagy markers in hearts from WT and APNKO mice. A: Representative gel blots depicting the levels of pan and phosphorylated AMPKα and mTOR, LC3B, p62 and α-tubulin
(loading control); B: p-AMPKα; C: p-AMPKα-to-AMPKα ratio; D: p-mTOR; E: p-mTOR-to-mTOR ratio; F: p62; G: LC3I; H: LC3II; and I: LC3II-to-LC3I ratio. Mean ± SEM, n = 4–
8 mice per group, *p b 0.05 vs. WT-LF group, #p b 0.05 vs. WT-HF group, †p b 0.05 vs. APNKO-HF group.
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phorylation, mTOR phosphorylation and p62 buildup, suggesting a cru-
cial role of autophagy in mediating the APN deﬁciency-accentuated
metabolic andmyocardial changes followinghigh fat intake. Theseﬁnd-
ings consolidated an essential role for APN as an important adipokine in
obesity and related cardiac anomalies through autophagy regulation.
Both experimental and clinical studies have depicted a unique role
for APN in cardiac homeostasis with reduced circulating APN levels
found in a number of pathological conditions such as obesity, insulin
resistance, atherosclerosis and coronary artery diseases [13]. Our data
showed that APN deﬁciency augmented high fat diet-induced glucose
intolerance and obesity with increased body weight, adipose mass
and serum triglyceride levels, in line with the reported role of APN
in glucose and lipid metabolism [51,52]. Intriguingly, calorie intake
was decreased along with a higher body weight gain in APNKO mice
following high fat diet intake. This may be due to a reduction in energy
expenditure and an increase in energy storage from high fat diet in
APNKOmice. Along the same line, O2 consumption and CO2 production
remained at low levels in APNKOmice consuming high fat diet, indicat-
ing that APN deﬁciency worsens high fat diet-induced reduction in me-
tabolism. Moreover, our results revealed higher RER in high fat diet-fedAPNKOmice comparedwith diet-matchedWTmice, suggesting a lesser
contribution of lipid oxidation for energy under APN deﬁciency. This is
in line with the fact that APN promotes lipid and fatty-acid oxidation
[29,53]. APNKO mice consuming high fat diet display disturbed fat oxi-
dation with a compensatory increase in carbohydrate oxidation. Our
observation indicated that WT mice consuming low fat diet depend
mainly on carbohydrate oxidation as their energy resource given the
RER value around 0.9 [54,55]. Meanwhile, APN deﬁciency lowered
physical activity and energy expenditure following high fat diet intake,
supporting a likely role for APN in the maintenance of energy balance
under condition of caloric surplus. In addition, 22 weeks of high fat diet
feeding triggered cardiac hypertrophy (heart weight, heart size and LV
mass, cardiomyocyte cross-sectional area), which were accentuated by
APNdeﬁciency.Meanwhile, resting cell lengthwas remarkably increased
in APNKOmice consuming high fat diet, consistent with the observation
that APN deﬁciency triggers severe cardiac hypertrophy following
pressure overload [56]whereas adenovirus-mediatedAPNdelivery atten-
uated pressure overload-induced cardiac hypertrophy in APN-deﬁcient
mice [19]. However, little difference was found in cardiac geometry and
function betweenWTandAPNKOmice consuming low fat diet, indicating
that APN deﬁciency itself may not innately be harmful to the heart.
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cardiomyocyte contractile anomalies (depressed PS, ±dL/dt, prolonged
TPS and TR90) in APNKO mice compared with WT mice following high
fat intake, indicating an essential role of APN in cardiac homeostasis
under stress conditions such as high fat diet intake. In addition, the in-
tensiﬁed intracellular Ca2+ derangement (reduced intracellular Ca2+
clearance and intracellular Ca2+ rise) in cardiomyocytes from high fat
diet-fed APNKO mice favors a possible role for APN in the maintenance
of cardiac intracellular Ca2+ homeostasis. The exacerbated cardiac con-
tractile dysfunction in APNKOmice consuming high fat diet is likely due
to disturbed lipid metabolism and cardiac geometry. Lipid deposition
around blood vessels in APNKO mice is perhaps indicative of adiposity
and onset of atherosclerotic plaque formation. Evidence from Lerman
and colleagues suggested that excess adiposity in obese individuals
may eventually lead to left ventricular dilation, increase wall stress and
diastolic dysfunction by elevating blood volume and cardiac output. It
is believed that toxic fatty-acid intermediates under high fat diet intake
may exert detrimental effects in such lipotoxic cardiomyopathy [37].
These data revealed an essential role for APN in the regulation of lipid
metabolism and pathogenesis of lipotoxic cardiovascular disorders.
Our ﬁndings displayed that high fat intake suppressed myocardial
autophagy as evidence by decreased LC3II level and the LC3II/LC3I
ratio with increased p62. APN deﬁciency further promoted p62 accu-
mulation but not LC3II conversation or Beclin-1 under high fat diet
intake, suggesting a potential role of suppressed autophagy in APN
deﬁciency-accentuated high fat diet response. This is supported by
the ﬁndings that autophagy induction using rapamycin effectively re-
versed high fat diet-induced and/or APN deﬁciency-accentuated body
weight gain, metabolic derangement (RER, physical activity, and energy
expenditure), cardiac hypertrophy and cardiac contractile anomalies.
Further scrutiny of autophagy regulatory proteins revealed overt AMPK
dephosphorylation and mTOR phosphorylation, both potent inhibitory
signals for autophagy, following high fat diet intake, the effects of which
were ampliﬁed by APN deﬁciency and mitigated by rapamycin. These
ﬁndings support a pivotal role of AMPK-dependent mTOR phosphoryla-
tion in high fat diet-induced/APN-accentuated suppression of autophagy.
Our results revealed that rapamycin treatment promoted and inhibited,
the phosphorylation of AMPK and mTOR, respectively, under either die-
tary condition. These ﬁndings are consistent with previous ﬁndings
where rapamycin directly stimulates AMPK and inhibits mTOR [57–59].
Consistent with AMPK phosphorylation and mTOR dephosphorylation,
rapamycin promoted autophagy as evidenced by increased LC3II
and LC3II-to-LC3I ratio as well as reduced p62 buildup, in agreement
with the previous ﬁndings [57–59]. These data are in line with the
previous ﬁndings where APN participates in the regulation of cell
survival and glucose metabolism through enhanced autophagic re-
sponse [60,61] and further consolidate a pivotal role for autophagy in
APN deﬁciency-accentuated changes in metabolism, cardiac geometry
and function upon high fat diet intake.
Recent evidence has demonstrated that autophagy is required for lipid
droplet breakdown (to remove unnecessary or excess lipid droplets).
Inhibition of autophagy disturbs lipid turnover and facilitates fat
storage [56,62]. In addition to the beneﬁcial actions of rapamycin treat-
ment on body weight gain, cardiac geometry and function in WT and
APNKO mice consuming high fat diet, our result also displayed that
rapamycin treatment in the face of high fat diet intake partially restored
carbohydrate oxidation and reduced lipid oxidation (as evidenced by
RER) in WT and APNKO mice. These ﬁndings were consistent with the
notion that rapamycin treatment favors fatty acids as a source of meta-
bolic fuel [63]. Although the RER value remains unchanged in high fat
diet-fed APNKO mice, rapamycin may possibly decrease body weight
gain and adipose tissue weight (including lipid accumulation) rather
than targeting on APN deﬁciency-induced abnormal fat oxidation. This
was conﬁrmed by our result that reduction in energy expenditure and
physical activity in response to high fat diet intake and/or APN deﬁcien-
cy were reversed by rapamycin. These ﬁndings indicate a role of APN inthe regulation of lipid metabolism. More interestingly, both in vivo and
ex vivo treatment of rapamycin attenuated high fat diet-induced deposi-
tion of fat droplets around cardiac blood vessels, indicating a role of
rapamycin in cardiac lipid metabolism. Obesity and disturbance of lipid
metabolism may be two main contributing factors for cardiac hypertro-
phy and contractile dysfunction, the effects of which may be reversed
by restoring autophagy using rapamycin. Last but not least, our current
ﬁnding favors presence of compromised autophagy following high fat
diet intake, consistent with recent reports [37,38]. However, increased
autophagywas also reported in response to lipid overload such as excess
cholesterol or fatty acids [64,65], as a cellular defense mechanism to re-
move the overloaded lipid. Further study is warranted to elucidate the
interplay between lipid spillover and autophagy in the setting of obesity.
In summary, data from our study offer evidence that APNmay play a
crucial role in high fat diet-induced obesity, metabolic derangement,
cardiac hypertrophy and contractile dysfunction through an AMPK/
mTOR-dependent regulation of autophagy. Restoration of autophagy
using rapamycin nulliﬁed APN deﬁciency-induced undesirable metabolic
and cardiac sequelae following high fat diet intake. These ﬁndings should
shed some light on the etiology of aberrant myocardial function and
remodeling in obesity, more importantly, the protective role of APN. In
consequence, APN and autophagy induction may serve as novel targets
for the management of obesity-associated myopathic and metabolic
changes.
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